Alpha Cognition Inc.ACOG
Price (close)
$8.47
Market cap
$184.5M
P/E
—
Revenue (TTM)
$15.3M
Net income
-$23.4M
Dividend yield
—
1-year total return
9.7%
Net margin
-153.6%
Revenue growth
—
Debt / equity
—
What Alpha Cognition Inc. does.
or no treatment options. We focus on the development of commercial manufacturing and commercial sales of ZUNVEYL oral tablet formulation.
Our commercial development program for ZUNVEYL is primarily focused on building a long-term care (“LTC”) commercial team that
can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors (“AChEI”)
Revenue and profit, by fiscal year.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | — | — | — | $10.2M |
| Net income | — | -$13.8M | -$14.8M | -$20.7M |
| Free cash flow | — | — | -$7.8M | -$20.7M |
More on ACOG.
- Alpha Cognition Inc. summary
- Alpha Cognition Inc. financial statements
- Alpha Cognition Inc. key metrics
- Alpha Cognition Inc. health scores and style box
- Alpha Cognition Inc. earnings
- Alpha Cognition Inc. dividends
- Alpha Cognition Inc. valuation
- Alpha Cognition Inc. ownership and insiders
- Alpha Cognition Inc. peers
Figures from Alpha Cognition Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.